Palisade Bio (PALI) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Palisade Bio

NasdaqCM•Healthcare•Biotechnology

$2.04-0.01(<0.01%)Market open

Market Cap

$336.10M

P/S

672.2x

P/B

2.8x

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

How this company scores

WeakMetricSide Score: 39/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability11/25

Growth7/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayInterest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1259.5x5y range 1259.5x – 1259.5x

P/S · 672.2x5y range 28.0x – 1639589.6x

Currently above its 6-quarter median.

P/B · 2.8x5y range 0.3x – 1045.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $336.10M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $500,000
Q. Revenue: $500,000
TTM EBITDA: $-35.35M
TTM Op. Income: $-35.35M
Q. Op. Income: $-11.70M
TTM Net Income: $-31.94M
Q. Net Income: $-10.57M
EPS: $-0.05
Shares Out.: $211.38M

$500,000 in TTM revenue grew from zero YoY, reaching $500,000 last quarter. TTM EBITDA of $-35.35M and TTM operating income of $-35.35M show growth is flowing through to the bottom line. However, net income is negative at $31.94M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 0% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -2339.6%
Op. Margin: -2339.6%
Net Margin: -2114.8%

Op. margin of -2339.6% is up 284297660.4% YoY — cost efficiency is improving. Net margin at -2114.8% Over the past year, operating margin is up 100% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 672.2x
P/B Ratio: 2.8x

P/S of 672.2x and P/B of 2.8x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $127.31M
Cash: $125.17M
Long-Term Debt: N/A
Book Value: $121.75M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-7.60M
TTM Free Cash Flow: $-18.19M
FCF Margin: -3638.0%
FCF / Net Income: 0.6

TTM FCF of $-18.19M on $-7.60M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.